PharmaCyte Biotech (NASDAQ:PMCB) Trading Up 2.4%

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) was up 2.4% during mid-day trading on Wednesday . The stock traded as high as $2.20 and last traded at $2.16. Approximately 6,203 shares were traded during trading, a decline of 72% from the average daily volume of 22,402 shares. The stock had previously closed at $2.11.

PharmaCyte Biotech Stock Up 2.4 %

The stock has a market cap of $18.25 million, a P/E ratio of -1.80 and a beta of -0.13. The firm has a 50 day simple moving average of $2.20 and a 200-day simple moving average of $2.19.

PharmaCyte Biotech (NASDAQ:PMCB) last announced its quarterly earnings results on Monday, March 18th. The company reported ($0.65) EPS for the quarter.

Institutional Investors Weigh In On PharmaCyte Biotech

A hedge fund recently bought a new stake in PharmaCyte Biotech stock. Sabby Management LLC acquired a new stake in PharmaCyte Biotech, Inc. (NASDAQ:PMCB) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 97,124 shares of the company’s stock, valued at approximately $204,000. PharmaCyte Biotech accounts for about 0.1% of Sabby Management LLC’s investment portfolio, making the stock its 27th largest holding. Sabby Management LLC owned approximately 1.11% of PharmaCyte Biotech at the end of the most recent quarter. 34.24% of the stock is currently owned by institutional investors and hedge funds.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc, a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes.